Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes
- PMID: 18645051
- DOI: 10.1161/HYPERTENSIONAHA.108.111120
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes
Abstract
We investigated whether aliskiren, a direct renin inhibitor, improves NO bioavailability and protects against spontaneous atherosclerotic changes. We also examined the effects of cotreatment with aliskiren and valsartan, an angiotensin II receptor blocker, on the above-mentioned outcomes. Watanabe heritable hyperlipidemic rabbits were treated with vehicle (control), aliskiren, valsartan, or aliskiren plus valsartan for 8 weeks. Then, acetylcholine-induced NO production was measured as a surrogate index of endothelium protective function, and both superoxide and vascular peroxynitrite were measured. Tetrahydrobiopterin in aortic segments was assessed by high-performance liquid chromatography with fluorescence detection. Plaque area was quantified by histology. Increase in plasma NO concentration in response to intra-aortic acetylcholine infusion was significantly greater in all of the test groups than in controls. Aliskiren+valsartan cotreatment increased acetylcholine-induced NO by 6.2 nmol/L, which was significantly higher than that with either aliskiren or valsartan alone. Vascular superoxide and peroxynitrite levels were both significantly higher in controls and significantly lower in the aliskiren+valsartan group than in the aliskiren or valsartan group. The highest tetrahydrobiopterin levels were observed after aliskiren+valsartan cotreatment. Histology of the thoracic aorta revealed that the plaque area was significantly decreased with combination therapy compared with monotherapy. Treatment with a direct renin inhibitor has protective effects on endothelial function and atherosclerotic changes. Furthermore, cotreatment with a direct renin inhibitor and an angiotensin II receptor blocker has additive protective effects on both.
Comment in
-
Aliskiren improves nitric oxide bioavailability and limits atherosclerosis.Hypertension. 2008 Sep;52(3):467-9. doi: 10.1161/HYPERTENSIONAHA.108.114488. Epub 2008 Jul 21. Hypertension. 2008. PMID: 18645047 No abstract available.
Similar articles
-
Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.Hypertension. 2009 Sep;54(3):633-8. doi: 10.1161/HYPERTENSIONAHA.109.133884. Epub 2009 Jul 13. Hypertension. 2009. PMID: 19597038
-
Combined effects of an 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and atherosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits.Hypertens Res. 2008 Jun;31(6):1199-208. doi: 10.1291/hypres.31.1199. Hypertens Res. 2008. PMID: 18716369
-
Effects of angiotensin converting enzyme inhibitor and angiotensin II receptor antagonist combination on nitric oxide bioavailability and atherosclerotic change in Watanabe heritable hyperlipidemic rabbits.Hypertens Res. 2008 Mar;31(3):575-84. doi: 10.1291/hypres.31.575. Hypertens Res. 2008. PMID: 18497479
-
The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.Drugs Today (Barc). 2010 Mar;46(3):151-62. doi: 10.1358/dot.2010.46.3.1437245. Drugs Today (Barc). 2010. PMID: 20467589 Review.
-
Aliskiren: renin inhibitor for hypertension management.Clin Ther. 2008 Jan;30(1):31-47. doi: 10.1016/j.clinthera.2008.01.011. Clin Ther. 2008. PMID: 18343241 Review.
Cited by
-
Angiotensin Regulation of Vascular Homeostasis: Exploring the Role of ROS and RAS Blockers.Int J Mol Sci. 2023 Jul 28;24(15):12111. doi: 10.3390/ijms241512111. Int J Mol Sci. 2023. PMID: 37569484 Free PMC article. Review.
-
Cerebral small vessel disease, systemic vascular characteristics and potential therapeutic targets.Aging (Albany NY). 2021 Sep 22;13(18):22030-22039. doi: 10.18632/aging.203557. Epub 2021 Sep 22. Aging (Albany NY). 2021. PMID: 34550097 Free PMC article.
-
Role of bone morphogenic protein-4 in gestational diabetes mellitus-related hypertension.Exp Ther Med. 2021 Jul;22(1):762. doi: 10.3892/etm.2021.10194. Epub 2021 May 13. Exp Ther Med. 2021. PMID: 34035859 Free PMC article.
-
Aliskiren Reduces the Adrenal Zona Glomerulosa Apoptosis and Autophagy in Wistar Rats with 2K1C Hypertension.Int J Hypertens. 2020 Oct 21;2020:7684849. doi: 10.1155/2020/7684849. eCollection 2020. Int J Hypertens. 2020. PMID: 33145109 Free PMC article.
-
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules.Bioorg Med Chem. 2020 May 15;28(10):115466. doi: 10.1016/j.bmc.2020.115466. Epub 2020 Mar 28. Bioorg Med Chem. 2020. PMID: 32247750 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical